These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30576763)

  • 1. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Li Y; Zhang KF; Lv Z; Chen XR; Wan LY; Wang W; Wang GM; Li DQ; Ai M; Kuang L
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():277-287. PubMed ID: 30576763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Lv Z; Chen XR; Wang W; Wang GM; Liu C; Li DQ; Kuang L
    J Psychiatr Res; 2019 Apr; 111():51-58. PubMed ID: 30677645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
    Maiti R; Mishra A; Srinivasan A; Mishra BR
    Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors.
    Gautam M
    J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):369-377. PubMed ID: 37335203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
    BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
    de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
    Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):453-66. PubMed ID: 21809258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.